Announces the FY2026 July results overview and business development activities. Cash and deposits of 5.3 billion yen, annual expenditure around 1.6 billion yen, and R&D expenditure about 1.49 billion yen. No revenue recognition from operations, no milestone income or upfront payments. Reports progress on the new pipeline and IP strategy, and progress on SR-GT1. Outlines future funding measures and development plans through 2028.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4599","jir_company_name":"StemRIM Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4599-20260911-01.pdf","jir_short_summary":"Announces the FY2026 July results overview and business development activities. Cash and deposits of 5.3 billion yen, annual expenditure around 1.6 billion yen, and R&D expenditure about 1.49 billion yen. No revenue recognition from operations, no milestone income or upfront payments. Reports progress on the new pipeline and IP strategy, and progress on SR-GT1. Outlines future funding measures and development plans through 2028.","jir_summary":"### Overview of the financial results\nThe FY2026 July results summary notes that no business revenue is generated and no milestone income or upfront payments are recognized. Cash and deposits amount to 5.3 billion yen, establishing a financially solid base to support stable R&D activities through 2028. Annual expenditures are around 1.6 billion yen, mainly comprising R&D costs.\n\n### Business development \/ IP \/ Outlook\nProgress in clinical development centered on Ledasemchod and SR-GT1, with IP strategy advancement reported. Disclosure of results from additional Phase 2\/Phase 2b, milestones such as orphan drug designation, and ongoing clinical trial progress. Going forward, development plans aiming for product launch in 2028, and anticipated creation of collaboration research and license revenue.","jir_financial_highlights":"Cash and deposits balance: 5.3 billion yen (as of end of July 2026)\nAnnual R&D expenses (P\/L basis): 1.49 billion yen (Actual for the year from Aug 2025 to Jul 2026)\nBusiness revenue: Unknown (For FY2026 July period, no milestone income or upfront payments recognized)\nOutlook for expenditures at present: 1.6 billion yen (Full-year amount for FY2026 July period)","jir_category":"","jir_hashtags":"#StemRIM, #Financial, #RegenerativeMedicine, #SR-GT1, #Ledasemchod","jir_key_figures":"Cash and deposits balance: 5.3 billion yen (as of end of July 2026)\nAnnual R&D expenses: 1.49 billion yen (year-long period Aug 2025\u2013Jul 2026)\nOutlook for expenditures: 1.6 billion yen (full-year FY2026, R&D 1.4 billion yen, SG&A 0.26 billion yen)","jir_meta_title":"\u3010StemRIM\u3011FY2026 July Earnings Summary and Business Development Activities\uff5cFunding Through 2028","jir_meta_description":"StemRIM FY2026 July earnings summary. Cash 5.3 billion yen, annual expenditures 1.6 billion yen, R&D expenses 1.49 billion yen. No milestone income; summary of Ledasemchod and SR-GT1 development progress and IP strategy. Confirmation of launch plan and future funding strategy.","jir_og_title":"StemRIM Earnings Summary and Development Outlook\uff5cFY2026 July","jir_og_description":"Report on earnings summary and business development. Cash 5.3 billion yen, annual expenditures 1.6 billion yen, R&D costs 1.49 billion yen. Progress on new drug candidates and IP strategy, with launch plans.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"[{x:'2025-08',y:0},{x:'2026-07',y:0}]\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"[{x:'2025-08',y:0},{x:'2026-07',y:0}]\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Profit Margin Trend\", \"jir_chart_json_data\": \"[{x:'2025-08',y:0},{x:'2026-07',y:0}]\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Forecast vs. Actual\", \"jir_chart_json_data\": \"[{x:'2025',y:0},{x:'2026',y:0}]\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Share\", \"jir_chart_json_data\": \"[]\"}]","ir_related_company":58113,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-113184","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n